Abstract
5-aminosalicylate (5-ASA) is widely prescribed for the treatment of inflammatory bowel disease (IBD) and prevention of inflammation-associated colorectal cancer (CRC). Its clinical effect is widely attributed to modulation of host inflammatory responses. However, the recent association of intestinal dysbiosis and selective enrichment in Escherichia coli in patients with IBD and CRC raises the possibility that 5-ASA might also affect the enteric microflora. The aim of this study was to investigate the effect of 5-ASA on the growth and virulence of E. coli associated with IBD and CRC, and its impact on host cell inflammatory responses. Our results show that 5-ASA inhibited E. coli growth in a dose-dependent manner and downregulated the expression of bacterial virulence genes associated with IBD (fliC, fimH, ompC, yfgL, nlpL, lpfA, htrA, dsbA, fyuA, and chuA) and CRC (pks). 5-ASA inhibited E. coli motility (30–70%), epithelial adherence and invasion, and IL-8 secretion (p < 0.05). 5-ASA reduced E. coli survival in J774A.1 macrophages by 20 to 50% (p < 0.01) and TNF-α secretion by infected macrophages up to 30% (p < 0.05). In addition, 5-ASA reduced DNA damage in epithelial cells (Caco-2) induced by pks-positive E. coli. Our results reveal a multifaceted and previously unrecognized effect of 5-ASA on the growth and virulence of IBD- and CRC-associated E. coli, in addition to its inhibitory effect on host cell inflammatory responses. These results suggest that 5-ASA may abrogate the proinflammatory and oncogenic effects of E. coli in patients with IBD and CRC.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Abdu-Allah HH, El Shorbagi A-NA, Abdel-Moty SG, El-Awady R, M Abdel-Alim A-A., 5-Aminosalyclic Acid (5-ASA): a unique anti-inflammatory salicylate. Med Chem. 2016;6:306–15.
Nielsen OH, Munck LK. Drug insight: aminosalicylates for the treatment of IBD. Nat Clin Pract Gastroenterol Hepatol. 2007;4:160–70.
Rubin DT, et al. Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: a clinical review and update. Inflamm Bowel Dis. 2008;14:265–74.
Ikeda I, et al. 5-Aminosalicylic acid given in the remission stage of colitis suppresses colitis-associated cancer in a mouse colitis model. Clin Cancer Res. 2007;13:6527–31.
Punchard NA, Greenfield SM, Thompson RP. Mechanism of action of 5-arninosalicylic acid. Mediat Inflamm. 1992;1:151–65.
Rachmilewitz D, Karmeli F, Schwartz LW, Simon PL. Effect of aminophenols (5-ASA and 4-ASA) on colonic interleukin-1 generation. Gut. 1992;33:929–32.
Kaiser GC, Yan F, Polk DB. Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes. Gastroenterol . 1999;116:602–9.
Egan LJ, et al. Inhibition of interleukin-1-stimulated NF-ĸb RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity. J Biol Chem. 1999;274:26448–53.
Dammann K, et al. PAK1 modulates a PPARγ/NF-ĸB cascade in intestinal inflammation. Biochim Biophys Acta. 2015;1853:2349–60.
Rousseaux C, et al. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med. 2005;201:1205–15.
Annese V, Rogai F, Settesoldi A, Bagnoli S. PPARγ in inflammatory bowel disease. PPAR Res. 2012;620839:9.
Vindigni SM, Zisman TL, Suskind DL, Damman CJ. The intestinal microbiome, barrier function, and immune system in inflammatory bowel disease: a tripartite pathophysiological circuit with implications for new therapeutic directions. Ther Adv Gastroenterol. 2016;9:606–25.
Chu H, et al. Gene-microbiota interactions contribute to the pathogenesis of inflammatory bowel disease. Sci. 2016;352:1116–20.
Sartor RB, Mazmanian SK. Intestinal microbes in inflammatory bowel diseases. Am J Gastroenterol Suppl. 2012;1:15–21.
Gagnière J, et al. Gut microbiota imbalance and colorectal cancer. World J Gastroenterol. 2016;22:501–18.
Arthur JC, et al. Microbial genomic analysis reveals the essential role of inflammation in bacteria-induced colorectal cancer. Nat Commun. 2014;5:4724.
Baumgart M, et al. Culture independent analysis of ileal mucosa reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to depletion of Clostridiales in Crohn’s disease involving the ileum. ISME J. 2007;1:403–18.
Darfeuille-Michaud A, et al. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn’s disease. Gastroenterol. 2004;127:412–21.
Simpson KW, et al. Adherent and invasive Escherichia coli is associated with granulomatous colitis in Boxer dogs. Infect Immun. 2006;74:4778–92.
Martin HM, et al. Enhanced Escherichia coli adherence and invasion in Crohn’s disease and colon cancer. Gastroenterol. 2004;127:80–93.
Khan AA, et al. Colorectal cancer-inflammatory bowel disease nexus and felony of Escherichia coli. Life Sci. 2017;180:60–7.
Arthur JC, et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Sci . 2012;338:120–3.
Cuevas-Ramos G, et al. Escherichia coli induces DNA damage in vivo and triggers genomic instability in mammalian cells. Proc Natl Acad Sci USA. 2010;107:11537–42.
Kaufman J, Griffiths TA, Surette MG, Ness S, Rioux KP. Effects of mesalamine (5-Aminosalicylic Acid) on bacterial gene expression. Inflamm Bowel Dis. 2009;15:985–96.
Greenstein RJ, Su L, Shahidi A, Brown ST. On the Action of 5-Amino-Salicylic Acid and Sulfapyridine on M. avium including Subspecies paratuberculosis. PLoS ONE. 2007;2:e516.
Swidsinski A, Weber J, Loening-baucke V, Hale LP, Lochs H. Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease. J Clin Microbiol. 2005;43:3380–9.
Kothary V, et al. Rifaximin resistance in Escherichia coli associated with inflammatory bowel disease correlates with prior rifaximin use, mutations in rpoB, and activity of Phe-Arg-β-Naphthylamide-inhibitable efflux pumps. Antimicrob Agents Chemother. 2013;57:811–7.
Kim SC, et al. Variable phenotypes of enterocolitis in interleukin 10-deficient mice monoassociated with two different commensal bacteria. Gastroenterol . 2005;128:891–906.
He Y, Xu T, Fossheim LE, Zhang XH. FliC, a Flagellin protein, is essential for the growth and virulence of fish pathogen Edwardsiella tarda. PLoS ONE. 2012;7:1–7.
Dogan B, et al. Inflammation-associated adherent-invasive Escherichia coli are enriched in pathways for use of propanediol and iron and M-cell translocation. Inflamm Bowel Dis. 2014;20:1919–32.
Bringer M-AA, Rolhion N, Glasser A-LL, Darfeuille-Michaud A. The oxidoreductase DsbA plays a key role in the ability of the Crohn’s disease-associated adherent-invasive Escherichia coli strain LF82 to resist macrophage killing. J Bacteriol. 2007;189:4860–71.
Bringer MA, Barnich N, Glasser AL, Bardot O, Darfeuille-Michaud A. HtrA stress protein is involved in intramacrophagic replication of adherent and invasive Escherichia coli strain LF82 isolated from a patient with Crohn’s disease. Infect Immun. 2005;73:712–21.
Rolhion N, Carvalho FA, Darfeuille-Michaud A. OmpC and the sigma(E) regulatory pathway are involved in adhesion and invasion of the Crohn’s disease-associated Escherichia coli strain LF82. Mol Microbiol. 2007;63:1684–700.
Barnich N, Bringer MA, Claret L, Daffeuille-Michaud A. Involvement of Lipoprotein NlpI in the virulence of adherent invasive Escherichia coli strain LF82 isolated from a patient with Crohn’s disease. Infect Immun. 2004;72:2484–93.
Barnich N, Boudeau J, Claret L, Darfeuille-Michaud A. Regulatory and functional co-operation of flagella and type 1 pill in adhesive and invasive abilities of AIEC strain LF82 isolated from a patient with Crohn’s disease. Mol Microbiol. 2003;48:781–94.
Prorok-Hamon M, et al. Colonic mucosa-associated diffusely adherent afaC + Escherichia coli expressing lpfA and pks are increased in inflammatory bowel disease and colon cancer. Gut. 2014;63:761–70.
Frieri G, et al. Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis. Gut. 2000;47:410–4.
Lane MC, et al. Role of motility in the colonization of uropathogenic Escherichia coli in the urinary tract. Infect Immun. 2005;73:7644–56.
Jung HC, et al. A distinct array of proinflammatory cytokines is expressed in human colon epithelial cells in response to bacterial invasion. J Clin Invest. 1995;95:55–65.
Lawrence T. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol. 2009;1:a001651.
Khanjani S, Terzidou V, Johnson MR, Bennett PR. NF-ĸB and AP-1 drive human myometrial IL8 expression. Mediat Inflamm. 2012;2012:504952.
Wang S, Liu Z, Wang L, Zhang X. NF-kappaB signaling pathway, inflammation and colorectal cancer. Cell Mol Immunol. 2009;6:327–34.
Ryan P, et al. Bacterial DNA within granulomas of patients with Crohn’s disease–detection by laser capture microdissection and PCR. Am J Gastroenterol. 2004;99:1539–43.
Deventer SJHVAN. Immunotherapy of Crohn’ s Disease. Scand J Immunol. 2000;51:18–22.
Healy AR, Nikolayevskiy H, Patel JR, Crawford JM, Herzon SB. A mechanistic model for colibactin-induced genotoxicity. J Am Chem Soc. 2016;138:15563–70.
Rahman K, Sasaki M, Nusrat A, Klapproth JMA. Crohn’s disease-associated Escherichia coli survive in macrophages by suppressing NFκB signaling. Inflamm Bowel Dis. 2014;20:1419–25.
Buc E, et al. High prevalence of mucosa-associated E. coli producing cyclomodulin and genotoxin in colon cancer. PLoS ONE. 2013;8:e56964.
Subramanian S, et al. Characterization of epithelial IL-8 response to inflammatory bowel disease mucosal E. coli and its inhibition by mesalamine. Inflamm Bowel Dis. 2008;14:162–75.
Sethi G, Sung B, Aggarwal BB. TNF: a master switch for inflammation to cancer. Front Biosci. 2008;13:5094–107.
Tak PP, Firestein GS, Tak PP, Firestein GS. NF-kappaB: a key role in inflammatory diseases. J Clin Invest. 2001;107:7–11.
Kaiser GC, Polk DB. Tumor necrosis factor alpha regulates proliferation in a mouse intestinal cell line. Gastroenterol. 1997;112:1231–40.
Nakajima A, et al. Endogenous PPAR gamma mediates anti-inflammatory activity in murine ischemia-reperfusion injury. Gastroenterol. 2001;120:460–9.
Straus DS, Glass CK. Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immun. 2007;28:551–8.
Acknowledgements
We are grateful for the support of Jill Roberts and Jill Roberts Center for IBD, Weill Cornell Medicine, New York, NY 10021, USA.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Electronic supplementary material
Rights and permissions
About this article
Cite this article
Zhang, S., Fu, J., Dogan, B. et al. 5-Aminosalicylic acid downregulates the growth and virulence of Escherichia coli associated with IBD and colorectal cancer, and upregulates host anti-inflammatory activity. J Antibiot 71, 950–961 (2018). https://doi.org/10.1038/s41429-018-0081-8
Received:
Revised:
Accepted:
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41429-018-0081-8
This article is cited by
-
The relationship between gut microbiota, lifestyle habits, and early-onset colorectal cancer: shedding light on early prediction
British Journal of Cancer (2025)
-
5-aminosalicylic acid alleviates colitis and protects intestinal barrier function by modulating gut microbiota in mice
Naunyn-Schmiedeberg's Archives of Pharmacology (2025)
-
Bidirectional Interplay Between IBD Therapies and the Gut Microbiota: A Pharmacomicrobiomic Approach to Personalized Treatment
BioDrugs (2025)
-
Anticolitic activity of prodigiosin loaded with selenium nanoparticles on acetic acid–induced colitis in rats
Environmental Science and Pollution Research (2022)
-
Ostarine attenuates pyocyanin in Pseudomonas aeruginosa by interfering with quorum sensing systems
The Journal of Antibiotics (2021)
